Literature DB >> 20516283

Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex.

Karin Bodewits, Christian R H Raetz, John R Govan, Dominic J Campopiano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20516283      PMCID： PMC2916346          DOI： 10.1128/AAC.01600-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  40 in total

Review 1.  Antibacterial and anti-inflammatory agents that target endotoxin.

Authors:  T J Wyckoff; C R Raetz; J E Jackman
Journal:  Trends Microbiol       Date:  1998-04       Impact factor: 17.079

2.  Antibacterial agents that inhibit lipid A biosynthesis.

Authors:  H R Onishi; B A Pelak; L S Gerckens; L L Silver; F M Kahan; M H Chen; A A Patchett; S M Galloway; S A Hyland; M S Anderson; C R Raetz
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

3.  Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.

Authors:  P Vandamme; B Holmes; M Vancanneyt; T Coenye; B Hoste; R Coopman; H Revets; S Lauwers; M Gillis; K Kersters; J R Govan
Journal:  Int J Syst Bacteriol       Date:  1997-10

4.  Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting.

Authors:  E Mahenthiralingam; M E Campbell; D A Henry; D P Speert
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

5.  UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme.

Authors:  J E Jackman; C R Raetz; C A Fierke
Journal:  Biochemistry       Date:  1999-02-09       Impact factor: 3.162

6.  Burkholderia (Pseudomonas) cepacia and cystic fibrosis: the epidemiology in Belgium.

Authors:  H Revets; P Vandamme; A Van Zeebroeck; K De Boeck; M J Struelens; J Verhaegen; J P Ursi; G Verschraegen; H Franckx; A Malfroot; I Dab; S Lauwers
Journal:  Acta Clin Belg       Date:  1996       Impact factor: 1.264

Review 7.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

8.  Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov.

Authors:  E Yabuuchi; Y Kosako; H Oyaizu; I Yano; H Hotta; Y Hashimoto; T Ezaki; M Arakawa
Journal:  Microbiol Immunol       Date:  1992       Impact factor: 1.955

9.  Transmission and prevalence of Burkholderia cepacia in Welsh cystic fibrosis patients.

Authors:  L Millar-Jones; H C Ryley; A Paull; M C Goodchild
Journal:  Respir Med       Date:  1998-02       Impact factor: 3.415

10.  Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak.

Authors:  M L Whiteford; J D Wilkinson; J H McColl; F M Conlon; J R Michie; T J Evans; J Y Paton
Journal:  Thorax       Date:  1995-11       Impact factor: 9.139
View more
  5 in total

Review 1.  Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.

Authors:  Alice L Erwin
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

2.  Mutants resistant to LpxC inhibitors by rebalancing cellular homeostasis.

Authors:  Daina Zeng; Jinshi Zhao; Hak Suk Chung; Ziqiang Guan; Christian R H Raetz; Pei Zhou
Journal:  J Biol Chem       Date:  2013-01-11       Impact factor: 5.157

3.  Characterization of an Acinetobacter baumannii lptD Deletion Strain: Permeability Defects and Response to Inhibition of Lipopolysaccharide and Fatty Acid Biosynthesis.

Authors:  Jade Bojkovic; Daryl L Richie; David A Six; Christopher M Rath; William S Sawyer; Qijun Hu; Charles R Dean
Journal:  J Bacteriol       Date:  2015-12-14       Impact factor: 3.490

4.  Targeted lipopolysaccharide biosynthetic intermediate analysis with normal-phase liquid chromatography mass spectrometry.

Authors:  William S Sawyer; Lisha Wang; Tsuyoshi Uehara; Pramila Tamrakar; Ramadevi Prathapam; Mina Mostafavi; Louis E Metzger; Brian Feng; Christopher M Baxter Rath
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

5.  Interplay of Klebsiella pneumoniae fabZ and lpxC Mutations Leads to LpxC Inhibitor-Dependent Growth Resulting from Loss of Membrane Homeostasis.

Authors:  Mina Mostafavi; Lisha Wang; Lili Xie; Kenneth T Takeoka; Daryl L Richie; Fergal Casey; Alexey Ruzin; William S Sawyer; Christopher M Rath; Jun-Rong Wei; Charles R Dean
Journal:  mSphere       Date:  2018-10-31       Impact factor: 4.389
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.